CR20210166A - Composiciones y métodos para el tratamiento de infecciones virales - Google Patents
Composiciones y métodos para el tratamiento de infecciones viralesInfo
- Publication number
- CR20210166A CR20210166A CR20210166A CR20210166A CR20210166A CR 20210166 A CR20210166 A CR 20210166A CR 20210166 A CR20210166 A CR 20210166A CR 20210166 A CR20210166 A CR 20210166A CR 20210166 A CR20210166 A CR 20210166A
- Authority
- CR
- Costa Rica
- Prior art keywords
- viral infections
- treatment
- compositions
- methods
- binding peptide
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 3
- 230000009385 viral infection Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010022005 Influenza viral infections Diseases 0.000 abstract 1
- 102000005348 Neuraminidase Human genes 0.000 abstract 1
- 108010006232 Neuraminidase Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 abstract 1
- 229960001084 peramivir Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 abstract 1
- 229960001028 zanamivir Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Las composiciones y métodos para el tratamiento de infecciones virales incluyen conjugados que contienen inhibidores de neuraminidasa viral (por ejemplo, zanamivir, peramivir o análogos de estos) unidos a un monómero de Fc, un dominio Fc y un péptido de unión a Fc, una proteína albúmina o péptido de unión a albúmina. En particular, los conjugados pueden utilizarse en el tratamiento de infecciones virales (por ejemplo, infecciones virales de influenza).
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862727821P | 2018-09-06 | 2018-09-06 | |
US201862746865P | 2018-10-17 | 2018-10-17 | |
US201862782119P | 2018-12-19 | 2018-12-19 | |
US201962788386P | 2019-01-04 | 2019-01-04 | |
US201962813463P | 2019-03-04 | 2019-03-04 | |
US201962815235P | 2019-03-07 | 2019-03-07 | |
US201962832992P | 2019-04-12 | 2019-04-12 | |
US201962840899P | 2019-04-30 | 2019-04-30 | |
US201962852075P | 2019-05-23 | 2019-05-23 | |
US201962859983P | 2019-06-11 | 2019-06-11 | |
US201962873678P | 2019-07-12 | 2019-07-12 | |
US201962890475P | 2019-08-22 | 2019-08-22 | |
PCT/US2019/050018 WO2020051498A1 (en) | 2018-09-06 | 2019-09-06 | Compositions and methods for the treatment of viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210166A true CR20210166A (es) | 2021-07-27 |
Family
ID=69722788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210166A CR20210166A (es) | 2018-09-06 | 2019-09-06 | Composiciones y métodos para el tratamiento de infecciones virales |
Country Status (16)
Country | Link |
---|---|
US (3) | US20210228727A1 (es) |
EP (1) | EP3846846A4 (es) |
JP (1) | JP2021536483A (es) |
KR (1) | KR20210079278A (es) |
CN (1) | CN113194983A (es) |
AU (2) | AU2019336230B2 (es) |
BR (1) | BR112021004266A2 (es) |
CA (1) | CA3111803A1 (es) |
CR (1) | CR20210166A (es) |
EC (1) | ECSP21023859A (es) |
IL (1) | IL281277A (es) |
MA (1) | MA53558A (es) |
MX (1) | MX2021002569A (es) |
PH (1) | PH12021550822A1 (es) |
SG (1) | SG11202103313RA (es) |
WO (1) | WO2020051498A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210079278A (ko) | 2018-09-06 | 2021-06-29 | 시다라 세라퓨틱스, 인코포레이티드 | 바이러스 감염의 치료를 위한 조성물 및 방법 |
TW202122117A (zh) | 2019-09-06 | 2021-06-16 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
US11253534B2 (en) | 2020-03-23 | 2022-02-22 | Sabine Hazan | Method of preventing COVID-19 infection |
US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
US11278520B2 (en) | 2020-03-31 | 2022-03-22 | Sabine Hazan | Method of preventing COVID-19 infection |
CA3175350A1 (en) * | 2020-03-23 | 2021-09-30 | Sabine HAZAN | Methods of preventing and treating covid-19 infection |
CN113801138A (zh) * | 2020-06-12 | 2021-12-17 | 博瑞生物医药(苏州)股份有限公司 | 一种一锅法制备辛酸拉尼米韦中间体的方法 |
TW202220698A (zh) | 2020-08-06 | 2022-06-01 | 美商席達拉醫療有限公司 | 蛋白質-藥物結合物之合成方法 |
CN116367866A (zh) | 2020-08-06 | 2023-06-30 | 奇达拉治疗公司 | 蛋白质-药物偶联物的合成方法 |
WO2022133281A1 (en) * | 2020-12-17 | 2022-06-23 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
CA3211494A1 (en) * | 2021-03-11 | 2022-09-15 | Leslie W. Tari | Protein-drug conjugates for antiviral therapy |
WO2023125806A1 (zh) * | 2021-12-30 | 2023-07-06 | 苏州爱科百发生物医药技术有限公司 | 用于预防和治疗病毒感染的偶联物及其用途 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0951480A4 (en) | 1996-11-14 | 2004-07-28 | Biota Scient Management | METHOD AND NEW CONNECTIONS THAT CAN BE USED IN THIS METHOD. |
US6495580B1 (en) | 1998-01-29 | 2002-12-17 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
AUPP913999A0 (en) | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
CZ20014574A3 (cs) | 1999-06-28 | 2002-05-15 | Janssen Pharmaceutica N. V. | Inhibitory replikace respiračně syncyciálního viru |
AUPR879701A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
CA2495266A1 (en) | 2002-08-09 | 2004-02-19 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
CN103893778A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
CN101802197A (zh) | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC(ScFc)区、包含其的结合多肽及与其相关的方法 |
US8518927B2 (en) | 2009-02-10 | 2013-08-27 | The Scripps Research Institute | Chemically programmed vaccination |
AU2011250970B2 (en) * | 2010-05-10 | 2016-12-15 | Sinica, Academia | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
PL2585467T3 (pl) | 2010-06-24 | 2016-09-30 | PIRAZOLO[1,5-A]PIRYMIDYNY i –TRIAZYNY JAKO ŚRODKI ANTYWIRUSOWE | |
ES2608835T3 (es) * | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
WO2014047357A1 (en) | 2012-09-21 | 2014-03-27 | The Regents Of The University Of California | Modified fc polypeptides, fc conjugates, and methods of use thereof |
PE20150723A1 (es) | 2012-10-16 | 2015-05-15 | Janssen Sciences Ireland Uc | Compuestos antiviricos para el vsr |
CA2903587C (en) | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
EP3024492A2 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Bioconjugates of synthetic apelin polypeptides |
WO2015022263A1 (en) | 2013-08-12 | 2015-02-19 | F. Hoffmann-La Roche Ag | Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為rsv抗病毒化合物之螺脲化合物 |
WO2017046625A1 (en) * | 2015-06-25 | 2017-03-23 | Cube Biotech Gmbh | New chelators for affinity purification of recombinant proteins |
WO2018006063A1 (en) | 2016-07-01 | 2018-01-04 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
US20230190950A1 (en) | 2017-01-06 | 2023-06-22 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
KR20210079278A (ko) | 2018-09-06 | 2021-06-29 | 시다라 세라퓨틱스, 인코포레이티드 | 바이러스 감염의 치료를 위한 조성물 및 방법 |
JP2022536740A (ja) | 2019-06-13 | 2022-08-18 | シダラ セラピューティクス インコーポレーテッド | ヒト免疫不全ウイルスの治療のための組成物及び方法 |
CN114390929A (zh) | 2019-06-13 | 2022-04-22 | 奇达拉治疗公司 | 用于治疗呼吸道合胞病毒的组合物及方法 |
TW202122117A (zh) | 2019-09-06 | 2021-06-16 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
-
2019
- 2019-09-06 KR KR1020217010062A patent/KR20210079278A/ko unknown
- 2019-09-06 CN CN201980072811.3A patent/CN113194983A/zh active Pending
- 2019-09-06 MA MA053558A patent/MA53558A/fr unknown
- 2019-09-06 CA CA3111803A patent/CA3111803A1/en active Pending
- 2019-09-06 WO PCT/US2019/050018 patent/WO2020051498A1/en unknown
- 2019-09-06 BR BR112021004266-0A patent/BR112021004266A2/pt unknown
- 2019-09-06 EP EP19857366.9A patent/EP3846846A4/en active Pending
- 2019-09-06 AU AU2019336230A patent/AU2019336230B2/en active Active
- 2019-09-06 CR CR20210166A patent/CR20210166A/es unknown
- 2019-09-06 MX MX2021002569A patent/MX2021002569A/es unknown
- 2019-09-06 JP JP2021512856A patent/JP2021536483A/ja active Pending
- 2019-09-06 SG SG11202103313RA patent/SG11202103313RA/en unknown
-
2021
- 2021-03-04 IL IL281277A patent/IL281277A/en unknown
- 2021-03-05 US US17/193,923 patent/US20210228727A1/en not_active Abandoned
- 2021-04-01 PH PH12021550822A patent/PH12021550822A1/en unknown
- 2021-04-06 EC ECSENADI202123859A patent/ECSP21023859A/es unknown
- 2021-04-21 US US17/236,722 patent/US11833213B2/en active Active
-
2023
- 2023-09-11 US US18/464,421 patent/US20240156975A1/en active Pending
- 2023-12-07 AU AU2023278077A patent/AU2023278077A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202103313RA (en) | 2021-04-29 |
US20220257787A1 (en) | 2022-08-18 |
TW202104176A (zh) | 2021-02-01 |
US11833213B2 (en) | 2023-12-05 |
AU2023278077A1 (en) | 2024-01-18 |
KR20210079278A (ko) | 2021-06-29 |
EP3846846A1 (en) | 2021-07-14 |
MX2021002569A (es) | 2021-06-08 |
US20240156975A1 (en) | 2024-05-16 |
AU2019336230B2 (en) | 2023-09-07 |
ECSP21023859A (es) | 2021-06-30 |
BR112021004266A2 (pt) | 2021-08-03 |
IL281277A (en) | 2021-04-29 |
WO2020051498A1 (en) | 2020-03-12 |
CA3111803A1 (en) | 2020-03-12 |
MA53558A (fr) | 2021-09-15 |
PH12021550822A1 (en) | 2021-10-04 |
AU2019336230A1 (en) | 2021-04-15 |
JP2021536483A (ja) | 2021-12-27 |
EP3846846A4 (en) | 2022-08-03 |
CN113194983A (zh) | 2021-07-30 |
US20210228727A1 (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550822A1 (en) | Compositions and methods for the treatment of viral infections | |
ZA202203681B (en) | Compositions and methods for the treatment of viral infections | |
EA201890735A1 (ru) | Модуляторы корового белка вируса гепатита b | |
EA202092808A1 (ru) | Вакцины на основе наночастиц с новыми структурными компонентами | |
CL2018002825A1 (es) | Vacuna contra vrs | |
EA201791086A1 (ru) | Человеческие антитела против гемагглютинина вируса гриппа | |
EP3967323A3 (en) | Hiv vaccine | |
PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
MY196095A (en) | Antibody That Binds to Envelope Glycoprotein of Severe Fever With Thrombocytopenia Syndrome Virus and use for Same | |
MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
PH12014502352A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition | |
WO2020252393A8 (en) | Compositions and methods for the treatment of human immunodeficiency virus | |
WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
EA202091769A1 (ru) | Вакцины против вируса гриппа и пути их применения | |
PH12019501064A1 (en) | Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
ECSP20083339A (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiple | |
MX2020000018A (es) | Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos. | |
MX2022016066A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
MX2022002842A (es) | Composiciones y metodos para el tratamiento del virus sincitial respiratorio. | |
MX2015012399A (es) | Conjugado de peptidos inmunogenicos y metodo para inducir una respuesta a un anticuerpo terapeutico anti-influenza con los mismos. | |
MX2015010763A (es) | Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento. | |
MX2018001298A (es) | Agente inductor de inmunidad. | |
TR201910305T4 (tr) | Viral enfeksiyonları tedavi etmek için bileşikler. |